The present invention concerns methods and reagents useful in modulating
Parkinson genes, for example, PARK1 (SNCA), PARK2, PARK7, and/or PARK5
gene expression in a variety of applications, including use in
therapeutic, diagnostic, target validation, and genomic discovery
applications. Specifically, the invention relates to small nucleic acid
molecules, such as short interfering nucleic acid (siNA), short
interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA),
and short hairpin RNA (shRNA) molecules capable of mediating RNA
interference (RNAi) against SNCA gene expression and/or activity. The
small nucleic acid molecules are useful in the diagnosis and treatment of
Parkinson Disease (PD), and any other disease or condition that responds
to modulation of PARK1 (SNCA), PARK2, PARK7, and/or PARK5 expression or
activity.
